
Ofatumumab is a disease-modifying therapy (DMT) that works by targeting a type of immune cell called a B cell. It is the first self-administered B-cell targeting therapy to be licensed in the UK. After initial guidance from a healthcare professional, ofatumumab can be self-injected at home. The licence is based on the results of two Phase III clinical trials, called… Read more »